PACMAN-AMI trial: review of endpoints

Czech version

Authors: Roman Margóczy ^1,2
Authors‘ workplace: II. klinika kardiológie a angiológie, LF Slovenskej zdravotnickej univerzity, Bratislava ¹; Oddelenie funkčnej diagnostiky, Stredoslovenský ústav srdcových a cievnych chorôb, Banská Bystrica ²
Published in: AtheroRev 2022; 7(3): 156-158
Category: Clinical Studies

Overview

Timely addition of alirocumab to high-intensity statin therapy in patients with myocardial infarction resulted in lipid profile improvement and significantly greater percent atheroma volume regression, assessed by combination of three intracoronary imaging modalities.

Keywords:

alirocumab – fibrous cap thickness (FCT) – intravascular ultrasonography (IVUS) – maximal lipid core burden index (maxLCBI) – near infrared spectroscopy (NIRS) – optical coherence tomography (OCT) – percent atheroma volume (PAV)

Sources

1. Räber L, Ueki Y, Otsuka T et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022; 327(18): 1771–1781. Dostupné z DOI: <http://10.1001/jama.2022.5218>.

Labels

Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Editorialy

Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies

Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin

Bempedoic acid – a new drug to lower LDL-cholesterol level

The importance of diet therapy and the correct regimen in familial hypercholesterolemia

What have imaging studies with evolocumab yielded?

Profesor Zdeněk Zadák pětaosmdesátiletý!

Research on remarkable articles from international literature

XXXVI. konference o hyperlipoproteinemiích – Šobrův den 2022

Article was published in

Athero Review

2022 Issue 3